𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Can a defect in bioenergetics be involved in the pathogenesis of Parkinson's disease after all?

✍ Scribed by Serge Przedborski

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
33 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Assessing quality of life in Parkinson's
Assessing quality of life in Parkinson's disease: Can a short-form questionnaire be useful?
✍ Zoe Katsarou; Sevasti Bostantjopoulou; Viv Peto; Anna Kafantari; Elizabeth Apost πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 621 KB

## Abstract Various instruments with good psychometric properties have been developed for the assessment of health‐related quality of life (HRQoL) in Parkinson's disease, (PD); however, in everyday practice a brief questionnaire is needed for quick screening of patients. We present the process of d

Role of apoptosis in the pathogenesis of
Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity?
✍ Ilan Ziv; Eldad Melamed πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 594 KB

The cause of the selective degeneration of nigrostriatal neurons in Parkinson's disease (PD) is still enigmatic. However, the last several years since the introduction of the concept of apoptosis have been characterized by exciting advances that may shed light on the process of the neuronal death un

Staging of Ξ±-synuclein in the olfactory
Staging of Ξ±-synuclein in the olfactory bulb in a model of Parkinson's disease: Cell types involved
✍ Isabel Ubeda-BaΓ±on; Daniel Saiz-Sanchez; Carlos de la Rosa-Prieto; Alicia Moheda πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 577 KB

## Abstract Impaired olfaction is an early symptom of Parkinson's disease. The underlying neuropathology likely includes α‐synucleinopathy in the olfactory bulb at an earlier stage (Braak's stage1) than pathology in the substantia nigra, which is not observed until stage 3. In this report, we inves

Leucine-rich repeat kinase 2 (LRRK2): A
Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease
✍ Payal N. Gandhi; Shu G. Chen; Amy L. Wilson-Delfosse πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 209 KB

## Abstract Parkinson's disease (PD) is the most common neurodegenerative movement disorder, with a prevalence of more than 1% after the age of 65 years. Mutations in the gene encoding leucine‐rich repeat kinase‐2 (__LRRK2__) have recently been linked to autosomal dominant, late‐onset PD that is cl